BRISBANE: CareDx Inc. has agreed to acquire precision oncology diagnostics company Naveris for up to $260 million, expanding its testing services beyond transplant medicine into cancer monitoring. The deal includes $160 million in upfront cash and up to $100 million tied to revenue milestones, the companies said. The transaction is expected to close in…
PARIS: French diagnostics group bioMérieux said on Thursday it has acquired U.S.-based Accellix, a developer of rapid, automated flow cytometry platforms, in a deal worth around €35 million. The acquisition strengthens bioMérieux’s pharmaceutical quality control business and expands its portfolio of solutions for advanced therapies, including cell and gene treatments. Accellix’s compact platform delivers…
SYDNEY: Proteomics International Laboratories Ltd (ASX: PIQ) announced on Wednesday the appointment of David Morris as Chief Executive Officer and Managing Director, effective January 19, 2026. Morris succeeds founder Dr. Richard Lipscombe, who will retire in February after 25 years leading the precision diagnostics company. Morris, a veteran healthcare and medical technology executive, has…
MELBOURNE – BioMarin Pharmaceutical Inc has agreed to acquire Amicus Therapeutics Inc in an all-cash deal valued at approximately $4.8 billion, the companies said on Monday. The acquisition includes Amicus’s commercial licensing contract for Dimerix Ltd’s experimental kidney disease therapy, DMX-200. Under the definitive agreement, BioMarin will assume all rights and obligations from Amicus…
ZURICH: Swiss drugmaker Novartis (NOVN.S) said on Sunday it has agreed to acquire U.S. biotech firm Avidity Biosciences (RNA.O) in a deal valued at approximately $12 billion, expanding its reach into the promising field of RNA therapeutics. Under the terms of the agreement, Novartis will pay $72 per share in cash for Avidity, representing…
LONDON: International Biotechnology Trust PLC announced Wednesday it has entered into an agreement with Schroders Capital to establish a partnership aimed at investing in unquoted biotechnology companies. The new partnership is designed to provide the Company’s shareholders with long-term access to a diversified portfolio of earlier-stage, private biotechnology firms. The Company intends to make…
Revenue rose to £105.6 million from £84.1 million exceeding expectations LONDON: Oxford Nanopore Technologies plc (LSE: ONT) on Tuesday reported a 28% year-on-year revenue increase on a constant currency basis for the first half of 2025, driven by broad-based growth across geographies and customer segments, and strong uptake of its PromethION sequencing platform. Revenue…
SAN DIEGO: Toragen Inc., a biotechnology company, announced that Dr. Sandra Coufal, M.D. will join Toragen as its new CEO. Dr. Coufal brings over 30 years of experience to Toragen as a physician and serial entrepreneur working with multiple successful companies in medicine, chemistry, biotechnology, material sciences, and digital technology. Most recently, Dr. Coufal…
TORONTO: Glow LifeTech Corp. (formerly Ateba Resources Inc.) will commence trading on the Canadian Securities Exchange (CSE) effective at the open of business on March 15, 2021, under the symbol “GLOW”. Clark Kent, CEO of the Company, commented, “Our public listing on the CSE is an important step forward for Glow and our shareholders,…
Charles River Laboratories Inc., is an American corporation specializing in a variety of preclinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted biomedical products and research and development outsourcing services for use in the pharmaceutical industry. According to its website, its customers include leading pharmaceutical, biotechnology,…